Convira Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-11-2024
- Paid Up Capital ₹ 0.11 M
as on 17-11-2024
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.95 M
as on 17-11-2024
- Satisfied Charges ₹ 2.00 M
as on 17-11-2024
- Revenue -18.75%
(FY 2023)
- Profit -56.41%
(FY 2023)
- Ebitda 139.41%
(FY 2023)
- Net Worth -1.79%
(FY 2023)
- Total Assets 2.53%
(FY 2023)
About Convira Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹0.95 M. The company has closed loans amounting to ₹2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sujeet Sahu and Payal Sahu serve as directors at the Company.
- CIN/LLPIN
U74120UP2012PTC048613
- Company No.
048613
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jan 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Convira Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujeet Sahu  | Managing Director | 30-Jan-2012 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Payal Sahu | Director | 30-Jan-2012 | Current |
Financial Performance of Convira Pharmaceuticals.
Convira Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 18.75% decrease. The company also saw a substantial fall in profitability, with a 56.41% decrease in profit. The company's net worth dipped by a decrease of 1.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Convira Pharmaceuticals?
In 2023, Convira Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Halcyon Drugs And Formulation Private LimitedActive 19 years 1 monthSujeet Sahu and Payal Sahu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Sep 2021 | ₹0.95 M | Open |
Bank Of India Creation Date: 27 Jul 2013 | ₹2.00 M | Satisfied |
How Many Employees Work at Convira Pharmaceuticals?
Unlock and access historical data on people associated with Convira Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Convira Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Convira Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
